169 related articles for article (PubMed ID: 10136601)
1. A pharmacoeconomic analysis of IV H2-receptor antagonist use in 40 hospitals.
Segal R; Oh T; Ben-Joseph R; Russell WL
Hosp Formul; 1994 May; 29(5):379-82, 388-91. PubMed ID: 10136601
[TBL] [Abstract][Full Text] [Related]
2. Strategy for developing a safe and cost-effective H2-receptor antagonist program.
Quercia RA; Chow MS; Jay GT; Quintiliani R
Hosp Formul; 1991 Nov; 26 Suppl D():20-4. PubMed ID: 10136561
[TBL] [Abstract][Full Text] [Related]
3. A practice-based approach for converting from proton pump inhibitors to less costly therapy.
Lucas LM; Gerrity MS; Anderson T
Eff Clin Pract; 2001; 4(6):263-70. PubMed ID: 11769299
[TBL] [Abstract][Full Text] [Related]
4. Criteria-based DUE aids in selection of preferred agent.
Drea EJ
Hosp Formul; 1991 Nov; 26 Suppl D():25-7. PubMed ID: 10136562
[TBL] [Abstract][Full Text] [Related]
5. Rational selection of H2-receptor antagonists for the hospital formulary. Roundtable discussion.
Keeffe EB; Harper JM; LeMay A; Sherrin TP; Siepler JK
Hosp Formul; 1991 Nov; 26 Suppl D():13-9. PubMed ID: 10136560
[No Abstract] [Full Text] [Related]
6. Implementing therapeutic interchange of intravenous famotidine for cimetidine and ranitidine.
Oh T; Franko TG
Am J Hosp Pharm; 1990 Jul; 47(7):1547-51. PubMed ID: 2114789
[TBL] [Abstract][Full Text] [Related]
7. Retrospective analysis of formulary restriction demonstrates significant cost savings.
Wetmore RW; Jennings RH
Hosp Formul; 1991 Nov; 26 Suppl D():30-2. PubMed ID: 10136564
[TBL] [Abstract][Full Text] [Related]
8. Reducing costs with formulary limitation of H2-receptor antagonists in a community hospital.
Coppola P
Hosp Pharm; 1991 Feb; 26(2):126-9, 142. PubMed ID: 10136547
[TBL] [Abstract][Full Text] [Related]
9. Use of i.v. cimetidine, ranitidine, and famotidine in 40 hospitals.
Segal R; Russell WL; Oh T; Ben-Joseph R
Am J Hosp Pharm; 1993 Oct; 50(10):2077-81. PubMed ID: 8238052
[TBL] [Abstract][Full Text] [Related]
10. Formulary designation of cimetidine as the primary intravenous histamine H2-receptor antagonist.
Berkowitz HS
Am J Hosp Pharm; 1992 Jan; 49(1):134-5. PubMed ID: 1349201
[No Abstract] [Full Text] [Related]
11. Therapeutic-interchange program for oral histamine H2-receptor antagonists.
Chase SL; Peterson AM; Wordell CJ
Am J Health Syst Pharm; 1998 Jul; 55(13):1382-6. PubMed ID: 9659966
[TBL] [Abstract][Full Text] [Related]
12. Pharmacy intern intervention to reduce costs associated with histamine H2-antagonist therapy.
Algozzine GJ; Sprenger RL; Caselnova DA; Proper P
Am J Hosp Pharm; 1989 Jun; 46(6):1183-4. PubMed ID: 2568750
[No Abstract] [Full Text] [Related]
13. Using multiple pharmacoeconomic methods to conduct a cost-effectiveness analysis of histamine H2-receptor antagonists.
McCoy S; Blayney-Chandramouli J; Mutnick A
Am J Health Syst Pharm; 1998 Dec; 55(24 Suppl 4):S8-12. PubMed ID: 9872687
[TBL] [Abstract][Full Text] [Related]
14. Effects of three H2-receptor antagonists (cimetidine, famotidine, ranitidine) on serum gastrin level.
Ohsawa T; Hirata W; Higichi S
Int J Clin Pharmacol Res; 2002; 22(2):29-35. PubMed ID: 12503773
[TBL] [Abstract][Full Text] [Related]
15. Effect of a criteria-based cost-containment program on the selection of oral H2-receptor antagonists.
Falbe WJ; Bess DT; Capers CC; Haymond JD; Stahl AA
Am J Hosp Pharm; 1992 Mar; 49(3):632-3. PubMed ID: 1598944
[No Abstract] [Full Text] [Related]
16. Evaluating the value, accuracy, and operational feasibility of DUE criteria.
Ben-Joseph R; Segal R; Russell WL; Oh T
Formulary; 1995 May; 30(5):280-3. PubMed ID: 10151727
[TBL] [Abstract][Full Text] [Related]
17. An analysis of potential and real cost savings by the addition of ranitidine to total parenteral nutrition solutions.
Pearson VE; King LM
Hosp Pharm; 1992 Jul; 27(7):610, 613-4. PubMed ID: 10119189
[TBL] [Abstract][Full Text] [Related]
18. Clinical appropriateness, therapeutic equivalence, and cost of conversion of H2 antagonist therapy.
Kitrenos JG; Brown DR; Letting DJ; Rotella DL
Hosp Formul; 1993 Jan; 28(1):86-8, 91, 95-6. PubMed ID: 10123271
[TBL] [Abstract][Full Text] [Related]
19. Pharmacoeconomic aspects and formulary considerations related to histamine2-receptor antagonists.
Souney PF; Stoukides CA
DICP; 1989 Oct; 23(10 Suppl):S29-35. PubMed ID: 2573207
[TBL] [Abstract][Full Text] [Related]
20. Decision analysis applied to selection of histamine H2-receptor antagonists for the formulary.
Calvo MV; Fruns I; DomÃnguez-Gil A
Am J Hosp Pharm; 1990 Sep; 47(9):2002-6. PubMed ID: 1977316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
